Anticancer Compounds Modulating RNA Splicing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer therapies, such as chemotherapeutic agents and radiation, are limited by adverse side effects and lack of specificity for cancer cells, necessitating the development of new anticancer therapeutics that can selectively target and inhibit cancer cell proliferation without harming normal cells.
Innovation Solution
Development of compounds that modulate RNA splicing and the spliceosome, specifically targeting cancer cells by interfering with the SF3b spliceosome subunit integration and U2 snRNP recruitment, thereby inhibiting cancer cell replication and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents and radiation are used to kill cancer cells, then cancer cell proliferation is inhibited, but normal cells are also damaged causing adverse side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures that selectively interact with cancer cell components. The compounds contain functional groups (R1-R6 substituents, leaving groups) that enable preferential binding to cancer cell targets while minimizing interaction with normal cells, achieving localized cytotoxic effect on cancer cells only
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the compounds (substituent types, positions, and configurations of R1-R6 groups, leaving group X) to optimize selectivity between cancer and normal cells. Different parameter combinations produce compounds with tuned cytotoxicity profiles that maximize cancer cell killing while reducing normal cell damage
2Reliability
If traditional chemotherapeutic agents are used, then cancer cell proliferation is suppressed, but the treatment lacks specificity for cancer cells
Solution Approach 1:
The patent implements local quality through molecular design where specific regions of the compound (functional groups R1-R6, leaving group X) are optimized for cancer cell target recognition. This localized structural optimization enables the compound to distinguish cancer cells from normal cells based on differences in cellular targets, achieving high cancer cell specificity
Solution Approach 2:
The patent applies segmentation by dividing the molecular structure into distinct functional segments (core structure with R1-R6 substituents, leaving group X) that can independently contribute to cancer cell specificity. Each segment can be optimized separately for different aspects of cancer cell targeting, allowing modular optimization of specificity
Data Source
AI summary
In one aspect, the invention relates to compounds having anticancer activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended to be used as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.